Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Mereo Biopharma Group plc (MREO)  
$2.71 0.05 (1.88%) as of 4:30 Mon 6/30


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 1,590,000,000
Market Cap: 4.31(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.76 - $4.87
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Mereo Biopharma Group is a biopharmaceutical company focused on the development and commercialization of therapeutics for oncology and rare diseases. Co. is developing etigilimab (OMP-313M32) for the treatment of solid tumors, alvelestat (MPH-966) for the treatment of severe alpha-1 antitrypsin deficiency, setrusumab (BPS-804) for the treatment of osteogenesis imperfecta, acumapimod (BCT-197) for the treatment of acute exacerbations of chronic obstructive pulmonary disease, leflutrozole (BGS-649) for the treatment of hypogonadotropic hypogonadism in obese men, and navicixizumab (OMP-305B83) for treatment of ovarian cancer.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 0 417,372 796,933
Total Sell Value $0 $0 $1,809,056 $3,079,681
Total People Sold 0 0 6 6
Total Sell Transactions 0 0 11 22
End Date 2025-03-30 2024-12-27 2024-06-28 2023-06-29

   
Records found: 40
  Page 1 of 2  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Hughes-Wilson Alexandra See Remarks   •       –      –    2024-09-13 4 S $4.22 $423,417 D/D (100,312) 50,475 32%     
   Pollard-Knight Denise Chief Executive Officer   •       •      –    2024-09-13 4 S $4.22 $253,454 D/D (60,046) 808,921 32%     
   Sermon Charles General Counsel   •       –      –    2024-09-13 4 S $4.22 $88,413 D/D (20,946) 219,061 32%     
   Lewicki John A. Chief Scientific Officer   •       –      –    2024-09-13 4 S $4.22 $46,165 D/D (10,937) 78,630 32%     
   Fox Chrisitne Ann Chief Financial Officer   •       –      –    2024-09-13 4 S $4.22 $80,866 D/D (19,158) 89,285 32%     
   Hughes-Wilson Alexandra See Remarks   •       –      –    2024-09-12 4 S $4.47 $213,786 D/D (47,798) 150,787 29%     
   Pollard-Knight Denise Chief Executive Officer   •       •      –    2024-09-12 4 S $4.47 $127,968 D/D (28,611) 868,967 29%     
   Sermon Charles General Counsel   •       –      –    2024-09-12 4 S $4.47 $44,638 D/D (9,980) 240,007 29%     
   Lewicki John A. Chief Scientific Officer   •       –      –    2024-09-12 4 S $4.47 $23,312 D/D (5,212) 89,567 29%     
   Fox Chrisitne Ann Chief Financial Officer   •       –      –    2024-09-12 4 S $4.47 $40,827 D/D (9,128) 108,443 29%     
   Hughes-Wilson Alexandra See Remarks   •       –      –    2024-09-11 4 OE $0.00 $206,416 D/D 208,333 242,881     -
   Pollard-Knight Denise Chief Executive Officer   •       •      –    2024-09-11 4 OE $0.00 $0 D/D 188,060 897,578     -
   Lewicki John A. Chief Scientific Officer   •       –      –    2024-09-11 4 OE $0.00 $0 D/D 46,000 94,779     -
   Fox Chrisitne Ann Chief Financial Officer   •       –      –    2024-09-11 4 OE $0.00 $0 D/D 60,000 117,571     -
   Sermon Charles General Counsel   •       –      –    2024-09-11 4 OE $0.00 $0 D/D 65,600 249,987     -
   Pakianathan Deepika   –       •      –    2024-08-22 4 S $4.43 $466,210 D/D (105,244) 0 22%     
   Pakianathan Deepika   –       •      –    2024-08-22 4 OE $0.94 $151,116 D/D 105,244 105,244     -
   Fox Chrisitne Ann Chief Financial Officer   •       –      –    2024-06-26 4 S $3.39 $99,892 D/D (29,439) 57,571 -15%     
   Hughes-Wilson Alexandra See Remarks   •       –      –    2024-06-26 4 S $3.39 $77,935 D/D (22,968) 34,548 -15%     
   Pollard-Knight Denise Chief Executive Officer   •       •      –    2024-06-26 4 S $3.39 $313,101 D/D (92,273) 709,518 -15%     
   Lewicki John A. Chief Scientific Officer   •       –      –    2024-06-26 4 S $3.39 $57,033 D/D (16,808) 48,779 -15%     
   Sermon Charles General Counsel   •       –      –    2024-06-26 4 S $3.39 $109,217 D/D (32,187) 184,387 -15%     
   Fox Chrisitne Ann Chief Financial Officer   •       –      –    2024-06-25 4 S $3.69 $47,984 D/D (12,990) 87,010 -22%     
   Hughes-Wilson Alexandra See Remarks   •       –      –    2024-06-25 4 S $3.69 $37,434 D/D (10,134) 57,516 -22%     
   Pollard-Knight Denise Chief Executive Officer   •       •      –    2024-06-25 4 S $3.69 $150,386 D/D (40,712) 801,791 -22%     
  40 Records found
  1  2   
  Page 1 of 2
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us